SPRN Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-09442
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the C-terminal region of Human SPRN (NP_001012526). Peptide sequence AAAGLAAGSGWRRAAGPGERGLEDEEDGVPGGNGTGPGIYSYRAWTSGAG
Clonality
Polyclonal
Host
Rabbit
Theoretical MW
10 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for SPRN Antibody
Western Blot: SPRN Antibody [NBP3-09442]
Western Blot: SPRN Antibody [NBP3-09442] - Western blot analysis of SPRN in HT1080 Whole Cell lysates. Antibody dilution at 1.0ug/mlApplications for SPRN Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: SPRN
Alternate Names
bA108K14.1, FLJ41197, Protein shadoo, SHADOO, shadow of prion protein, shadow of prion protein homolog (zebrafish), SHOShadoo, Sprn
Gene Symbol
SPRN
Additional SPRN Products
Product Specific Notices for SPRN Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...